TY - JOUR
T1 - Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update
AU - Scaldaferri, Franco
AU - Gerardi, Viviana
AU - Mangiola, Francesca
AU - Lopetuso, Loris Riccardo
AU - Pizzoferrato, Marco
AU - Petito, Valentina
AU - Papa, Alfredo
AU - Stojanovic, Jovana
AU - Poscia, Andrea
AU - Cammarota, Giovanni
AU - Gasbarrini, Antonio
PY - 2016
Y1 - 2016
N2 - Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor® (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of EcN.
AB - Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor® (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of EcN.
KW - Escherichia coli Nissle
KW - Gastroenterology
KW - Inflammatory bowel disease
KW - Metanalysis
KW - Probiotic
KW - Randomized trial
KW - Ulcerative colitis
KW - Escherichia coli Nissle
KW - Gastroenterology
KW - Inflammatory bowel disease
KW - Metanalysis
KW - Probiotic
KW - Randomized trial
KW - Ulcerative colitis
UR - http://hdl.handle.net/10807/93889
UR - http://www.wjgnet.com/esps/downloadfile.aspx?type=digital&subtype=1&doi=10.3748%2fwjg.v22.i24.5505&filepath=pub%5c10.3748%5cv22%5ci24%5cwjg-22-5505.pdf
U2 - 10.3748/wjg.v22.i24.5505
DO - 10.3748/wjg.v22.i24.5505
M3 - Article
SN - 1007-9327
VL - 22
SP - 5505
EP - 5511
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
ER -